Blocking MCT4 SUMOylation inhibits the growth of breast cancer cells

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Monocarboxylate transporter 4 (MCT4) is upregulated in solid tumors, including breast cancer (BC).
• The precise mechanisms driving MCT4's pro-tumorigenic functions remain unclear.
• Posttranslational modifications (PTMs) are critical regulators of protein stability and function.

Purpose of the Study:

• To investigate the role of PTMs, specifically SUMOylation, in regulating MCT4 protein levels in breast cancer.
• To identify key residues and interacting proteins involved in MCT4 modification.
• To explore the therapeutic potential of targeting MCT4 PTMs in BC.

Main Methods:

• Western blotting and immunoprecipitation to assess protein levels and interactions.
• Site-directed mutagenesis to probe the function of specific lysine residues.
• Analysis of MCT4 ubiquitination and SUMOylation status in BC cells.

Main Results:

• SUMOylation of MCT4 inhibits its degradation, leading to increased protein stability.
• Ubiquitination promotes MCT4 degradation, mediated by E3 ligases β-TRCP and FBW7.
• Lysine 448 (K448) is identified as the critical site for MCT4 SUMOylation.
• Mutating K448 abrogates MCT4 expression and significantly delays BC tumor growth.

Conclusions:

• SUMOylation at K448 is a key mechanism stabilizing MCT4 in breast cancer.
• Targeting K448 SUMOylation or mutating this residue represents a promising therapeutic strategy for BC.
• Understanding MCT4 PTMs provides insights into cancer metabolism and potential drug targets.